2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1757

B Cell Activating Factor Receptor Expression After Rituximab: Comparison of Patients with Rheumatoid Arthritis and Thrombotic Thrombocytopenic Purpura
Abstract Number: 1764

B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease
Abstract Number: 610

B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation
Abstract Number: 482

B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
Abstract Number: 618

BAFF/BLyS Gene Expression Predicts Disease Activity in Systemic Lupus Erythematosis Over One Year
Abstract Number: 2429

Balancing Work and Health: Do Younger Workers Experience More Work-Health Conflict Than Middle- and Older-Aged Workers with Rheumatic Diseases?
Abstract Number: 1577

Barriers to Recruit Unaffected Family Members of Patients with Rheumatoid Arthritis
Abstract Number: 1234

Barriers, Benefits and Preferences for Exercise in RA Patients: A Cross Sectional Study
Abstract Number: 398

Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Abstract Number: 1237

Baseline Evaluation of Insulin Resistance in Patients with early Non-Treated Rheumatoid Arthritis
Abstract Number: 2158

Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Abstract Number: 1107

Baseline Knee Flexion Pain, Age and Joint Line Tenderness Predict the Progression of Asymptomatic, Radiographic Knee Osteoarthritis to Symptomatic Knee Osteoarthritis Over 5 Years
Abstract Number: 615

Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials Are Predictive of Severe Flare At 52 Weeks
Abstract Number: 1573

Baseline Screening Recommendations for Rheumatoid Arthritis Patients Treated with Disease Modifying Anti-Rheumatic Drugs: Does an Educational Intervention Change Practice in an Outpatient Clinic?
Abstract Number: 431

Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA
Abstract Number: 601

Bath Ankylosing Spondylitis Functional Index (BASFI) Is a Better Indicator of Poor Quality of Life Than Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in Ankylosing Spondylitis: Results From SIRAS – the Scotland and Ireland Registry for Ankylosing Spondylitis
Abstract Number: 2376

Behcet’s Disease: Combination of Pulse Cyclophosphamide, Azathioprine, and Prednisolone for the Treatment of Retinal Vasculitis; Longitudinal Study On 10 Years
Abstract Number: 1341

Beneficial Effect of Anti-TNF Therapy in the Lipoprotein Atherogenic Risk Profile in Comparison with DMARD Standard Therapy in RA Patients
Abstract Number: 757

Beneficial Role of Rapamycin in Experimental Autoimmune Myositis
Abstract Number: 2652

Benefits of Aerobic Training in Patients with Ankylosing Spondylitis Are Not Coupled by Effects On Cytokines: A Randomized Controlled Trial
Abstract Number: 2695

Benefits of the Chronic Disease Self-Management Program in Low-Income African American Women with Systemic Lupus Erythematosus: Results of a Pilot Test
Abstract Number: 84

Benefits of Treat-to-Target Guideline Compliance in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Abstract Number: 1562

Benign Joint Hypermobility Syndrome More Common Than Expected,Both in Controls and in SLE Patients
Abstract Number: 458

Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database
Abstract Number: 616

Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Abstract Number: 457

Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Abstract Number: 2638

Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Abstract Number: 1801

Biological Roles of C5orf30 in Rheumatoid Arthritis
Abstract Number: 1642

Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Abstract Number: 1923

Biologics in Relapsing Polychondritis: A Single Center Case-Series
Abstract Number: 1709

Biomarkers of Atherosclerosis Are Associated with Progression of Non-Cardiovascular Damage in Patients with SLE
Abstract Number: 2498

Biomarkers of Mitochondrial Dysfunction Correlate with Disease Activity in SLE
Abstract Number: 719

Biomarkers of Pulmonary Hypertension in Patients with Scleroderma: A Case-Control Study
Abstract Number: 790

Biomechanical Function Agrees with Clinical Implications of Foot Disorders in a Population-Based Study
Abstract Number: 1512

Bleomycin Delivery by Osmotic Pump: A Superior Model for Human ILD
Abstract Number: L6

Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Abstract Number: 332

Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation
Abstract Number: 2681

Blocking the Serum Protease Inhibitor Activity of Plasminogen Activator Inhibitor-1 Protects Mice From Development of Glomerulonephritis in a Model of Lupus Nephritis
Abstract Number: 2392

Blood Vessel Instability and Oxidative Damage in Giant Cell Arteritis
Abstract Number: 312

Blood-Based Biomarkers of Neurocognitive Dysfunction in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 800

BMI, Occupational Activity, and Leisure-Time Physical Activity: an Exploration of Risk Factors and Modifiers for Knee Osteoarthritis
Abstract Number: 2395

Body Composition, Strength, and Function in Elderly Patients with Giant Cell Arteritis
Abstract Number: 478

Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis
Abstract Number: 2582

Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Abstract Number: 2072

Bone Formation and Resorption Are Both Increased in Autoimmune Arthritis
Abstract Number: 1010

Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies
Abstract Number: 271

Bone Marrow Lesions in Knees with Osteoarthritis: Can Parameters From Dynamic Contrast Enhancement Predict Change in Bone Marrow Lesion Volume or Knee Pain Change?
Abstract Number: 38

Bone Marrow Lesions On Magnetic Resonance Imaging Are Not Associated with Regions of Hypermetabolism in an Animal Model of Osteoarthritis
Abstract Number: 1958

Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Abstract Number: 2583

Bone Structure and Perfusion Quantification of Bone Marrow Edema and Pannus Tissue Areas in the Wrist of Patients with RA
Abstract Number: 125

Borderline Right Ventricular Involvement in Patients with Systemic Sclerosis without Pulmonary Hypertension
Abstract Number: 295

Brain Biopsy Diagnosis in Magnetic Resonance Imaging Negative Childhood Primary Angiitis of the Central Nervous System
Abstract Number: 587

Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis
Abstract Number: 2525

Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants
Abstract Number: 2526

Bruton′s Tyrosine Kinase and Calreticulin: A Novel Interaction with Implications for Inflammatory and Autoimmune Disease
Abstract Number: 1856

Burden of Adverse Events Associated with Immunosuppressant Therapy for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review
Abstract Number: 304

Burden of Childhood Central Nervous System Vasculitis: Identifying High Risk Factors for Poor Cognitive Outcome
Abstract Number: 1017

Bye Bye Biopsy: Diffusion Tensor and Dynamic Contrast Enhance Magnetic Resonance Imaging Parameters Reflect Molecular Events of Inflammation in the Synovium

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].